Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

10x Genomics (TXG) EBIAT (2018 - 2025)

10x Genomics' EBIAT history spans 8 years, with the latest figure at -$16.3 million for Q4 2025.

  • For Q4 2025, EBIAT rose 66.85% year-over-year to -$16.3 million; the TTM value through Dec 2025 reached -$43.5 million, up 76.16%, while the annual FY2025 figure was -$43.5 million, 76.16% up from the prior year.
  • EBIAT for Q4 2025 was -$16.3 million at 10x Genomics, up from -$27.5 million in the prior quarter.
  • Across five years, EBIAT topped out at $34.5 million in Q2 2025 and bottomed at -$93.0 million in Q3 2023.
  • The 5-year median for EBIAT is -$36.8 million (2024), against an average of -$35.3 million.
  • The largest annual shift saw EBIAT crashed 483.22% in 2022 before it soared 191.14% in 2025.
  • A 5-year view of EBIAT shows it stood at -$18.4 million in 2021, then increased by 6.69% to -$17.2 million in 2022, then plummeted by 184.36% to -$49.0 million in 2023, then decreased by 0.16% to -$49.0 million in 2024, then soared by 66.85% to -$16.3 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's EBIAT are -$16.3 million (Q4 2025), -$27.5 million (Q3 2025), and $34.5 million (Q2 2025).